Integra Lifesciences Holdings (IART) news
Recent news
Integra LifeSciences Holdings Corp (IART.O): UBS initiates coverage with neutral rating; target price $19
AInvest Wire · Jul 28, 2026Integra LifeSciences appoints Topaz Kirlew chief regulatory officer
AInvest Wire · Jul 2, 2026Integra LifeSciences Holdings Corp (IART.O): Argus Research raises to buy from hold
Argus Research analyst David Toung has upgraded Integra LifeSciences (NASDAQ: IART) from Hold to Buy, citing improved market positioning and operational progress . The firm assigned a $28 price target, reflecting expectations of stronger sequential revenue and profit growth as supply constraints…
AInvest Wire · Jun 18, 2026SpliSense: secures up to $13 mln from Cystic Fibrosis Foundation to advance Phase 2B study of SPL84 for Cystic Fibrosis
SpliSense, a clinical-stage biotechnology company focused on RNA-based therapies for pulmonary diseases, has secured up to $8.5 million in additional funding from the Cystic Fibrosis Foundation (CFF) to advance Phase 2 clinical trial of SPL84 , an inhaled antisense oligonucleotide (ASO) candidate…
AInvest Wire · Jun 16, 2026Vita Life Sciences - guides H1 2026 sales at A$46.3 mln-A$47.3 mln
Integra LifeSciences (Nasdaq: IART) reported its first-quarter 2026 financial results on May 5, 2026, showing mixed performance across its business segments. Total reported revenues for the quarter reached $391.9 million, reflecting a 2.4% increase compared to the prior year and 1.3% organic growth…
AInvest Wire · Jun 12, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.